AERIE PHARMACEUTICALS INC's ticker is AERI and the CUSIP is 00771V108. A total of 159 filers reported holding AERIE PHARMACEUTICALS INC in Q2 2020. The put-call ratio across all filers is 2.23 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2022 | $8,671,000 | -17.6% | 1,156,142 | 0.0% | 0.11% | -5.2% |
Q1 2022 | $10,521,000 | +29.6% | 1,156,142 | 0.0% | 0.12% | +49.4% |
Q4 2021 | $8,116,000 | -38.4% | 1,156,142 | 0.0% | 0.08% | -43.0% |
Q3 2021 | $13,180,000 | -28.8% | 1,156,142 | 0.0% | 0.14% | -29.3% |
Q2 2021 | $18,510,000 | -10.4% | 1,156,142 | 0.0% | 0.19% | -5.4% |
Q1 2021 | $20,660,000 | +5.0% | 1,156,142 | -20.6% | 0.20% | +2.5% |
Q4 2020 | $19,672,000 | +14.8% | 1,456,142 | 0.0% | 0.20% | +2.1% |
Q3 2020 | $17,139,000 | +108.8% | 1,456,142 | +161.8% | 0.19% | +101.0% |
Q2 2020 | $8,209,000 | +9.3% | 556,142 | 0.0% | 0.10% | -8.6% |
Q1 2020 | $7,508,000 | -44.1% | 556,142 | 0.0% | 0.10% | -34.8% |
Q4 2019 | $13,442,000 | +25.8% | 556,142 | 0.0% | 0.16% | +18.4% |
Q3 2019 | $10,689,000 | -20.7% | 556,142 | +21.9% | 0.14% | -19.0% |
Q2 2019 | $13,479,000 | +108.4% | 456,142 | +235.0% | 0.17% | +104.9% |
Q1 2019 | $6,467,000 | +121.1% | 136,142 | +68.0% | 0.08% | +95.2% |
Q4 2018 | $2,925,000 | -56.1% | 81,015 | -25.2% | 0.04% | -51.2% |
Q3 2018 | $6,664,000 | -11.0% | 108,266 | -2.3% | 0.09% | -17.3% |
Q2 2018 | $7,487,000 | +89.7% | 110,838 | +52.4% | 0.10% | +70.5% |
Q1 2018 | $3,946,000 | -19.6% | 72,739 | -11.5% | 0.06% | -14.1% |
Q4 2017 | $4,911,000 | +13.1% | 82,188 | -8.1% | 0.07% | +14.5% |
Q3 2017 | $4,344,000 | -7.7% | 89,384 | -0.2% | 0.06% | -12.7% |
Q2 2017 | $4,706,000 | +36.4% | 89,549 | +17.7% | 0.07% | +22.4% |
Q1 2017 | $3,451,000 | +26.5% | 76,091 | +5.6% | 0.06% | +9.4% |
Q4 2016 | $2,728,000 | -48.9% | 72,083 | -49.1% | 0.05% | -43.6% |
Q3 2016 | $5,340,000 | +58.0% | 141,500 | -26.3% | 0.09% | +44.6% |
Q2 2016 | $3,379,000 | +44.7% | 192,006 | 0.0% | 0.06% | +44.4% |
Q1 2016 | $2,335,000 | -50.1% | 192,006 | 0.0% | 0.04% | -45.1% |
Q4 2015 | $4,675,000 | +30.9% | 192,006 | -4.6% | 0.08% | +36.7% |
Q3 2015 | $3,572,000 | -69.0% | 201,350 | -69.2% | 0.06% | -26.8% |
Q2 2015 | $11,526,000 | +304.6% | 653,006 | +618.4% | 0.08% | +100.0% |
Q1 2015 | $2,849,000 | +7.4% | 90,903 | 0.0% | 0.04% | +5.1% |
Q4 2014 | $2,653,000 | -1.4% | 90,903 | -30.1% | 0.04% | -2.5% |
Q3 2014 | $2,691,000 | – | 130,000 | – | 0.04% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Foresite Capital Management II, LLC | 906,317 | $16,078,000 | 4.88% |
Asymmetry Capital Management, L.P. | 85,834 | $1,523,000 | 3.39% |
March Altus Capital Management LP | 30,962 | $549,000 | 3.23% |
DAFNA Capital Management LLC | 165,669 | $2,939,000 | 2.92% |
Partner Investment Management, L.P. | 49,726 | $882,000 | 1.33% |
Boulegeris Investments, Inc. | 93,320 | $1,655,000 | 1.27% |
PFM Health Sciences, LP | 2,218,198 | $39,351,000 | 1.11% |
NORTHPOINTE CAPITAL LLC | 443,125 | $7,861,000 | 1.02% |
HARVEY CAPITAL MANAGEMENT INC | 121,850 | $2,161,000 | 0.86% |
Granite Point Capital Management, L.P. | 70,000 | $1,242,000 | 0.85% |